Canakinumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hereditary Periodic Fevers
Conditions
Hereditary Periodic Fevers
Trial Timeline
Jun 27, 2014 → Jul 4, 2017
NCT ID
NCT02059291About Canakinumab + Placebo
Canakinumab + Placebo is a phase 3 stage product being developed by Novartis for Hereditary Periodic Fevers. The current trial status is completed. This product is registered under clinical trial identifier NCT02059291. Target conditions include Hereditary Periodic Fevers.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05725343 | Phase 3 | Terminated |
| NCT04510493 | Phase 3 | Completed |
| NCT04362813 | Phase 3 | Completed |
| NCT03447769 | Phase 3 | Terminated |
| NCT02059291 | Phase 3 | Completed |
| NCT01390350 | Phase 2 | Completed |
| NCT00889863 | Phase 3 | Completed |
| NCT00886769 | Phase 3 | Terminated |
| NCT00581945 | Phase 1/2 | Completed |
| NCT00424346 | Phase 2 | Completed |
Competing Products
20 competing products in Hereditary Periodic Fevers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KVD900 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| KVD900 + Placebo to KVD900 | KalVista Pharmaceuticals | Phase 1 | 28 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| Placebo + KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD900 600 mg + Drug: KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Deferasirox FCT | Novartis | Phase 2 | 52 |
| Ilaris | Novartis | Pre-clinical | 23 |
| Standard of Care for Haemophilia A | Roche | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Phase 1 | 32 |
| Nitisinone | Swedish Orphan Biovitrum | Pre-clinical | 22 |